
New Service for
TodaysSeniorsNetwork.com readers...roll mouse over, click on
highlighted links in stories to review items from Amazon
Study
projects 60 percent increase In ESRD
population by 2020
Newswise — Although estimates have been
adjusted downward in light of the most
recent data, researchers still predict sharp
increases in the U.S. incidence and
prevalence of end-stage renal disease (ESRD)
in the years ahead, according to a paper
being presented at the American Society of
Nephrology's 40th Annual Meeting and
Scientific Exposition in San Francisco.
"The expected number of patients with ESRD
in 2020 is almost 785,000, which is an
increase of over 60 percent compared to
2005," comments Dr. David T. Gilbertson of
the U.S. Renal Data System (USRDS) and the
Minneapolis Medical Research Foundation,
Minneapolis, Minn. Using data available
through 2005, the study updates previous
estimates based on data through 2000.
The researchers used statistical techniques
to project available data on the ESRD
population to the year 2020. The model took
into account a wide range of factors,
including expected trends in population
growth and the rising rate of diabetes—the
main cause of kidney disease. The study also
incorporated the latest data on the risk of
progression to ESRD once kidney disease is
present.
Based on the results, Dr. Gilbertson and
colleagues predict that the U.S. incidence
(number of new cases) of ESRD will be about
135,000 in 2015. This figure is about 3,000
lower than the previous estimate.
For
reasons that are not entirely clear, the
incidence of ESRD has been decreasing in
recent years, and the updated figure
accounts for that trend. The predicted
prevalence (total number of cases) of ESRD
in 2015 is estimated at 680,000—about 33,000
less than the previous estimate.
Nevertheless, based on a combination of
trends—including the aging of the "Baby
Boomer" population, rising diabetes rates,
and improvements kidney disease treatment
allowing better survival—the authors project
continued increases in numbers of Americans
affected by ESRD. By 2020, the incidence
(new cases) of ESRD is expected to rise to
151,000 per year (compared to 107,000 in
2005). Prevalence (all cases) is expected to
increase to 785,000 (compared to 485,000 in
2005).
"These projections play an important role in
shaping public health policy and health care
planning related to the treatment of kidney
disease," says Dr. Gilbertson. "Medicare
pays for the care for the vast majority of
patients with ESRD, with costs approaching
$60,000 per year for every patient."
The predictions suggest that, despite recent
declines in new cases, policymakers should
account for continued increases in the
health and economic impact of ESRD in the
United States. "While relatively flat ESRD
incidence rates may show some progress
towards Healthy People 2010 goals of
reducing ESRD incidence, it is important to
know the expected future counts of patients,
as opposed to rates, to inform public health
policy and health care planning related to
the treatment of kidney disease," Dr.
Gilbertson says. "The financial and human
resources that will be needed to care for
these patients in 2020 will be
considerable."
The study abstract, "Projecting the ESRD
Population to 2020," (SA-FC046) will be
presented as part of a Free Communications
session on the topic of “Epidemiology and
Consequences of Chronic Kidney Disease” on
Saturday, November 3 at 4:00 PM in Room 2009
of the Moscone Center.
The ASN is a not-for-profit organization of
10,500 physicians and scientists dedicated
to the study of nephrology and committed to
providing a forum for the promulgation of
information regarding the latest research
and clinical findings on kidney diseases.
ASN’s Renal Week 2007, the largest
nephrology meeting of its kind, will provide
a forum for 11,000 nephrologists, to discuss
the latest findings in renal research and
engage in educational sessions relating
advances in the care of patients with kidney
and related disorders from October 31 –
November 5 at the Moscone Center in San
Francisco, CA.
...
...
...